Tumor biomarkers contribute to the diagnosis and clinical management of the O-RADS MRI risk stratification system for epithelial ovarian tumors

Table 3 Differences in tumor biomarkers of EOTs among the O-RADS MRI 3, 4, and 5 categories

Variable		O-RADS MRI 3	O-RADS MRI 4	O-RADS MRI 5	Reference level
CA125 (U/mL)	BeEOT	18.34 ± 25.98	/	/	0–35
	BEOT	84.64 ± 152.3	92.02 ± 124.2	62.82 ± 68.68
	MEOT	321.1 ± 397.3	496.1 ± 780.8	703.9 ± 867.1
	P value	< 0.0001^abc	< 0.0001	0.0008
ROMA index (%) Premenopausal	BeEOT	5.952 ± 3.182	/	/	< 11.4
	BEOT	9.877 ± 6.591	11.84 ± 13.86	7.366 ± 5.455
	MEOT	25.92 ± 17.32	43.45 ± 29.52	74.71 ± 31.24
	P value	< 0.0001^abc	< 0.0001	< 0.0001
ROMA index (%) Postmenopausal	BeEOT	10.59 ± 3.032	/	/	< 29.9
	BEOT	30.48 ± 24.10	/	/
	MEOT	40.78 ± 26.39	61.10 ± 31.22	73.06 ± 29.75
	P value	0.0102^ac	/	/

/: not applicable
^a The difference between benign and borderline EOTs was statistically significant
^b The difference between borderline and malignant EOTs was statistically significant
^c The difference between benign and malignant EOTs was statistically significant

ISSN: 1477-7819